ArticleAnnals of medicine2025
The distribution of colposcopy directed ectocervical biopsy and endocervical curettage results: a retrospective study of 47,134 cases.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Additional Diagnostic Yield of Endocervical Curettage in Type 3 Transformation Zone for High-Grade Cervical Lesions: A Retrospective Analysis by Human Papillomavirus Genotype.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the distribution of colposcopy directed ectocervical biopsy and endocervical curettage (ECC) results, and to identify patients who may benefit from ECC.
methodsThis retrospective study analyzed the clinical data of 47,134 patients who underwent colposcopy directed ectocervical biopsy and ECC between January 2021 and December 2023. Risk factors were identified by univariate and multivariate logistic analyses.
resultsThe positive rate of the final histopathological diagnosis was 37.1% (17,503/47,134), with 22.8% (10,724/47,134) for low-grade squamous intraepithelial lesion (LSIL) and 14.4% (6,779/47,134) for high-grade squamous intraepithelial lesion (HSIL) or worse lesions (≥HSIL). At final diagnosis of LSIL, HSIL, adenocarcinoma
conclusionsECC is a useful procedure for detecting additional endocervical lesions, and is recommended for patients aged ≥ 45, with high-risk HPV infection, ASC-H + or AGC cytology, and TZ3, as it will help reduce the rate of missed diagnosis of cervical lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.